Clinical Approach to Medical Management of Type 2 Diabetes
Clinical Approach to Medical Management of Type 2 Diabetes
Clinical Approach to Medical Management of Type 2 Diabetes
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Metformin Versus Active Compara<strong>to</strong>rs<br />
Study<br />
Characteristics<br />
N=289, 33 weeks,<br />
baseline A1c 8.2-8.4%<br />
N=486, 16 weeks,<br />
baseline A1c 8.5-8.8%<br />
N=1199, 52 weeks,<br />
baseline A1c 8.7%<br />
N=1091, 24 weeks,<br />
baseline A1c 8.6-8.8%<br />
N=820, 26 weeks<br />
baseline A1c 8.4-8.6%<br />
Metformin<br />
or Placebo<br />
A1c Effect<br />
Metformin<br />
vs. Placebo -1.4% +0.4%<br />
vs. Glyburide<br />
vs. Glyburide/Metformin<br />
-1.5% -1.9%<br />
-2.3%<br />
vs. Pioglitazone -1.5% -1.4%<br />
vs. Sitagliptin<br />
vs. Sitagliptin/Metformin<br />
vs. Exenatide LAR<br />
vs. Sitagliptin<br />
vs. Pioglitazone<br />
-1.13%<br />
(max dose)<br />
A1c Effect<br />
Compara<strong>to</strong>r<br />
-0.66%<br />
-1.90%<br />
-1.5% ExeLAR -1.5%<br />
Sita -1.2%<br />
Pio -1.6%<br />
1. Defronzo et al, NEJM, 1995 2.Garber et al, JCEM, 2003 3. Schernanter et al, JCEM, 2004<br />
4.Goldstein et al, <strong>Diabetes</strong> Care, 2007. 5.Russel-Jones et al, <strong>Diabetes</strong> Care, 2012
Change language